12:26 , Oct 19, 2018 |  BC Extra  |  Financial News

Ahead of Phase II, TP raises $80M mezzanine round

Oncology company TP Therapeutics Inc. (San Diego, Calif.) raised $80 million in a mezzanine round and promoted Athena Countouriotis to CEO from CMO as the company readies to begin a potentially registrational Phase II study...
20:32 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Genentech reports ORR of 77.4% for entrectinib in pooled analysis of ROS1-positive NSCLC patients

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported data from an integrated analysis of 53 patients with locally advanced or metastatic c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1)-positive non-small cell lung cancer (NSCLC) in...
17:06 , Aug 23, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling TrkB fusion oncogenes and mutations could help predict sensitivity to the TrkA/TrkB/TrkC inhibitor larotrectinib in patients with blood cancers. Genomic sequencing of 7,311 patients with hematologic malignancies identified one TrkA, one TrkB and...
15:55 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Cell and rat studies identified three TrkA/TrkB/TrkC inhibitors that could help treat pain. Screening of a small molecule library in cell-based activity assays yielded three analogs of a core scaffold -- a piperidine-pyridine compound,...
01:43 , Jun 9, 2018 |  BioCentury  |  Product Development

Past not prologue

Loxo Oncology Inc.’s two-year streak of stunning data at ASCO appears to be the result of good decisions on the back of a healthy dose of luck. But it will be a tall order to...
19:16 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Priority review for Loxo's larotrectinib in tissue-agnostic indication

FDA accepted and granted Priority Review to an NDA for larotrectinib (LOXO-101) from Loxo Oncology Inc. (NASDAQ:LOXO) to treat locally advanced or metastatic solid tumors with neurotrophic tyrosine kinase receptor (Trk) fusion proteins, regardless of...
14:43 , May 29, 2018 |  BC Extra  |  Company News

Priority Review for Loxo's larotrectinib in tissue-agnostic indication

FDA accepted and granted Priority Review to an NDA for larotrectinib (LOXO-101) from Loxo Oncology Inc. (NASDAQ:LOXO) to treat locally advanced or metastatic solid tumors with neurotrophic tyrosine kinase receptor (Trk) fusion proteins, regardless of...
22:56 , May 22, 2018 |  BC Extra  |  Tools & Techniques

Trinity identifies hurdles for tissue-agnostic therapies

While the use of basket trials to test therapies in tissue agnostic, biomarker-based cancer indications is increasing, the long-term implications rely on a handful of factors, many of which may affect postmarket uptake of agents...
16:52 , Apr 13, 2018 |  BC Week In Review  |  Company News

Veracyte, Loxo team up for TRK, RET targeted therapies

Molecular diagnostics company Veracyte Inc. (NASDAQ:VCYT) said Loxo Oncology Inc. (NASDAQ:LOXO) will use Veracyte's Afirma Xpression Atlas platform to develop targeted therapies for thyroid cancers with tropomyosin receptor kinase (TRK) fusions and Ret proto-oncogene (RET)...
15:38 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

Loxo completes larotrectinib NDA

Loxo Oncology Inc. (NASDAQ:LOXO) completed submission of a rolling NDA to FDA for larotrectinib (LOXO-101) to treat locally advanced or metastatic solid tumors with neurotrophic tyrosine kinase receptor (Trk) fusion-proteins, regardless of tissue of origin. Larotrectinib...